We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Trial Evaluating

News List

Provention Bio Initiates Trial Evaluating PRV-3279 in Lupus americanpharmaceuticalreview
August 09, 2019
Provention Bio has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase 1b/2a clinical trial evaluating PRV-3279. PRV-3279 is a humanized diabody (a bispecific scaffold biologic molecule) targeting the B-cell surface prote
First Subject Dosed In Phase 1 Trial Evaluating INP105 americanpharmaceuticalreview
August 30, 2018
Impel NeuroPharma announced the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-and-active controlled crossover study of their intranasal olanzapine product, INP105, dosed via Impel's proprietary Precision Olfactory Delivery,